Trending Stock News

Brookside Capital Management Has Increased Its Clovis Oncology (CLVS) Stake; 0 Analysts Are Bullish Pendragon PLC (LON:PDG) Last Week

Brookside Capital Management Llc increased Clovis Oncology Inc (CLVS) stake by 206.23% reported in 2017Q2 SEC filing. Brookside Capital Management Llc acquired 94,658 shares as Clovis Oncology Inc (CLVS)’s stock declined 20.61%. The Brookside Capital Management Llc holds 140,558 shares with $13.16 million value, up from 45,900 last quarter. Clovis Oncology Inc now has $3.14B valuation. The stock decreased 0.02% or $0.01 during the last trading session, reaching $64.13. About 2.03 million shares traded or 52.22% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since December 17, 2016 and is uptrending. It has outperformed by 266.01% the S&P500.

Among 6 analysts covering Pendragon PLC (LON:PDG), 0 have Buy rating, 1 Sell and 5 Hold. Therefore 0 are positive. Pendragon PLC had 54 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Pendragon PLC (LON:PDG) has “Buy” rating given on Monday, October 5 by Liberum Capital. As per Tuesday, October 25, the company rating was maintained by Liberum Capital. Jefferies maintained the stock with “Buy” rating in Tuesday, August 4 report. On Tuesday, November 17 the stock rating was maintained by Liberum Capital with “Buy”. The firm has “Buy” rating given on Monday, October 12 by Liberum Capital. As per Tuesday, October 27, the company rating was maintained by Liberum Capital. Liberum Capital maintained Pendragon PLC (LON:PDG) rating on Monday, November 23. Liberum Capital has “Buy” rating and GBX 50 target. On Friday, May 5 the stock rating was maintained by Jefferies with “Buy”. Berenberg maintained it with “Buy” rating and GBX 52 target in Friday, August 21 report. Liberum Capital maintained Pendragon PLC (LON:PDG) on Monday, November 30 with “Buy” rating. See Pendragon PLC (LON:PDG) latest ratings:

04/12/2017 Broker: Berenberg Rating: Hold Old Target: GBX 26.00 New Target: GBX 26.00 Maintain
04/12/2017 Broker: Canaccord Genuity Rating: Hold Old Target: GBX 26.00 New Target: GBX 26.00 Maintain
04/12/2017 Broker: Liberum Capital Rating: Hold Old Target: GBX 26.00 New Target: GBX 26.00 Maintain
01/12/2017 Broker: JP Morgan Rating: Underweight New Target: GBX 17.00 Initiates Starts
10/11/2017 Broker: Jefferies Rating: Hold Old Target: GBX 55.00 New Target: GBX 25.00 Downgrade
24/10/2017 Broker: Numis Securities Rating: Hold New Target: GBX 25.00 Maintain
23/10/2017 Broker: Liberum Capital Rating: Under Review Old Target: GBX 43.00 Under Review
01/08/2017 Broker: Canaccord Genuity Rating: Hold New Target: GBX 36.00 Maintain
01/08/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 43.00 New Target: GBX 43.00 Maintain
28/07/2017 Broker: Jefferies Rating: Buy Old Target: GBX 55.00 New Target: GBX 55.00 Maintain

Investors sentiment decreased to 1.44 in 2017 Q2. Its down 0.37, from 1.81 in 2017Q1. It worsened, as 33 investors sold CLVS shares while 56 reduced holdings. 74 funds opened positions while 87 raised stakes. 46.46 million shares or 12.58% more from 41.27 million shares in 2017Q1 were reported. Moreover, Strs Ohio has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS). Endurant Cap Mngmt Ltd Partnership owns 0.84% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 31,650 shares. Raymond James accumulated 7,581 shares. Point72 Asia (Hong Kong) Limited reported 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Paloma Prtn Management Company holds 0.01% or 4,800 shares in its portfolio. Cypress Cap Limited Liability (Wy) owns 550 shares for 0% of their portfolio. Columbus Circle reported 122,532 shares. Farallon Cap Mgmt Llc reported 610,000 shares stake. C Grp Incorporated Hldg A S has 223,560 shares for 0.32% of their portfolio. Partner Fund Ltd Partnership reported 0.93% stake. Advsrs Asset Mngmt reported 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Fmr Ltd Limited Liability Company holds 0.02% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 1.73M shares. Marshall Wace Ltd Liability Partnership has invested 0.03% in Clovis Oncology, Inc. (NASDAQ:CLVS). Hbk Limited Partnership accumulated 0.11% or 125,406 shares. Tocqueville Asset Mgmt Lp accumulated 0.06% or 57,125 shares.

Brookside Capital Management Llc decreased Quintiles Ims Holdings Inc (NYSE:Q) stake by 74,899 shares to 536,657 valued at $48.03M in 2017Q2. It also reduced Astrazeneca Plc (Call) (NYSE:AZN) stake by 30,000 shares and now owns 10,000 shares. Vertex Pharmaceuticals Inc (Call) (NASDAQ:VRTX) was reduced too.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology had 54 analyst reports since September 10, 2015 according to SRatingsIntel. As per Monday, April 4, the company rating was reinitiated by Piper Jaffray. As per Friday, February 3, the company rating was downgraded by Chardan Capital Markets. The stock has “Buy” rating by Bank of America on Wednesday, August 2. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Friday, January 27 by Bank of America. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, January 23 report. The firm has “Hold” rating given on Tuesday, November 17 by WallachBeth Capital. The rating was upgraded by JP Morgan on Wednesday, May 17 to “Overweight”. On Thursday, November 2 the stock rating was maintained by Morgan Stanley with “Overweight”. The firm has “Buy” rating by J.P. Morgan given on Thursday, June 1. RBC Capital Markets maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Thursday, November 2 with “Hold” rating.

Since August 4, 2017, it had 0 buys, and 4 sales for $2.12 million activity. Shares for $208,500 were sold by IVERS-READ GILLIAN C on Friday, September 15. $1.45M worth of Clovis Oncology, Inc. (NASDAQ:CLVS) shares were sold by BLAIR JAMES C.

Pendragon PLC, together with its subsidiaries, operates as an automotive retailer firm in the United Kingdom and California. The company has market cap of 400.60 million GBP. It operates through seven divisions: Stratstone, Evans Halshaw, US Motor Group, Pinewood, Leasing, Quickco, and Central. It has a 6.73 P/E ratio. The firm sells new and used motor vehicles under the Aston Martin, BMW, Ferrari, Jaguar, Land Rover, Mercedes-Benz, MINI, Morgan, Porsche, Smart, Harley-Davidson, Citroen, Dacia, Ford, Honda, Hyundai, Kia, Nissan, Peugeot, Renault, SEAT, and Vauxhall brands.

The stock increased 1.80% or GBX 0.5 during the last trading session, reaching GBX 28.25. About 2.66 million shares traded. Pendragon PLC (LON:PDG) has 0.00% since December 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *